Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:GSD CVE:KNE CVE:LTY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.82-2.1%$3.62$3.96▼$12.00$6.85M1.557,305 shs3,794 shsGSDGlobal System Dynamics$11.11$11.16$9.90▼$11.98$36.77MN/A7,280 shs2 shsKNEKane BiotechC$0.04C$0.05C$0.04▼C$0.16C$5.76M0.5271,856 shs115,000 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+2.63%-1.52%+13.70%+6.56%-32.76%GSDGlobal System Dynamics0.00%0.00%0.00%0.00%0.00%KNEKane Biotech0.00%-11.11%-27.27%-50.00%-73.33%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AGSDGlobal System DynamicsN/AN/AN/AN/AN/AN/AN/AN/AKNEKane BiotechN/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AGSDGlobal System Dynamics 0.00N/AN/AN/AKNEKane Biotech 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.89N/AN/A$14.99 per share0.25GSDGlobal System DynamicsN/AN/AN/AN/A($1.84) per shareN/AKNEKane BiotechC$1.42M4.05C$0.00 per share8.50C($0.01) per share-7.77LTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)GSDGlobal System Dynamics-$790KN/A0.00∞N/AN/AN/A-2.30%N/AKNEKane BiotechC$6.03MC$0.041.00∞N/A423.52%-94.49%-58.43%N/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AGSDGlobal System DynamicsN/AN/AN/AN/AN/AKNEKane BiotechN/A3.08%N/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93GSDGlobal System DynamicsN/A0.010.01KNEKane Biotech-331.420.800.39LTYLiberty Biopharma8.190.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%GSDGlobal System Dynamics24.82%KNEKane BiotechN/ALTYLiberty BiopharmaN/AInsider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%GSDGlobal System Dynamics62.81%KNEKane Biotech37.21%LTYLiberty BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataGSDGlobal System DynamicsN/A3.31 million1.23 millionNot OptionableKNEKane BiotechN/A144.06 millionN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableKNE, AEZS, GSD, and LTY HeadlinesRecent News About These CompaniesTelefonica Is Said to Draw Up Plans for Liberty’s VMO2 StakeMay 15, 2025 | bloomberg.comMoms for Liberty wants funds cut to Alabama libraries that let kids check out ‘pornographic material’January 11, 2024 | al.comARight wing Moms for Liberty group making moves in staunchly blue ManhattanJanuary 9, 2024 | nydailynews.comWhy Liberty Latin America Ltd. (LILA) Has an Undervalued Rating?January 3, 2024 | msn.comABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesJanuary 3, 2024 | markets.businessinsider.comLiberty Hospital is still recovering systems days after cyber attackDecember 29, 2023 | bizjournals.comMicrobot’s Liberty Robotic System Meets Objectives in Pivotal Preclinical StudyDecember 28, 2023 | evtoday.comERedhill Biopharma Ltd ADRDecember 27, 2023 | morningstar.comMMoms for Liberty faces growing challenges amid Florida sex scandalDecember 23, 2023 | news.yahoo.comOne Liberty (OLP) Completes Asset Sale Worth $63M in 2023December 22, 2023 | msn.comDelayed Liberty Hospital surgery could cost patient thousands if IT issues continueDecember 20, 2023 | msn.comLiberty Travel Partners with Affirm to Bring Travelers a More Flexible Way to Book TripsDecember 18, 2023 | tmcnet.comLiberty 99, St. Andrews 26December 16, 2023 | sfgate.comHere's Why Liberty Park Capital's Short Position in Powell Industries (POWL) DetractedDecember 16, 2023 | msn.comLiberty Home Guard reviewDecember 13, 2023 | usatoday.comLiberty Shoes Ltd (LIBERTSHOE) Share PriceDecember 12, 2023 | businesstoday.inBLiberty Media to merge unit with SiriusXM to create new public companyDecember 12, 2023 | reuters.comMoms for Liberty's vision for America's future is narrow and dark. Why not help kids?December 7, 2023 | news.yahoo.comLDDFF Liberty Defense Holdings, Ltd.November 29, 2023 | seekingalpha.comRedHill Biopharma Shares Double on FDA's 5-Year Market Exclusivity GrantNovember 27, 2023 | marketwatch.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness?By Dan Schmidt | July 7, 2025View Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness?KNE, AEZS, GSD, and LTY Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.82 -0.08 (-2.05%) As of 08/1/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Global System Dynamics NASDAQ:GSDGlobal System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.Kane Biotech CVE:KNEC$0.04 0.00 (0.00%) As of 08/1/2025 02:17 PM EasternKane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
